Clinical trials have found that GlaxoSmithKline’s anti-blood clotting drug Arixtra nearly halved the risk of blood clots in acutely ill patients, a result that is expected to boost the commercial prospects of Brisbane-based Alchemia’s (ASX:ACL) generic version of the drug. More...
